Objective: To compare the efficacy, safety and tolerability of valsartan to an angiotensin-
converting enzyme (ACE) inhibitor, lisinopril, and placebo in patients with mild-to-moderate …

Objective: To compare the antihypertensive efficacy and systemic tolerability of valsartan, a
new angiotensin II receptor antagonist, with placebo and with an angiotensin converting …

Objective: To study the efficacy and tolerability of a range of valsartan doses in patients with
mild-to-moderate hypertension. Design: 122 adult out-patients were randomised in equal …

Objective: To compare the antihypertensive efficacy of a new angiotensin II antagonist,
valsartan, with a reference therapy, hydrochlorothiazide (HCTZ). Methods: In this double …

The aim of this study was to evaluate the efficacy and tolerability of valsartan, a new
angiotensin II receptor antagonist, versus atenolol in the treatment of severe primary …

Synopsis Valsartan competitively and selectively inhibits the actions of angiotensin II at the
AT 1 receptor subtype which is responsible for most of the known effects of angiotensin II. In …

Background: The goal of antihypertensive therapy is to provide good blood pressure (BP)
control without eliciting adverse effects. Objective: This study compared the risk-benefit …

A multicenter, randomized, placebo-controlled, double-masked, parallel-group study was
performed to compare the efficacy and safety of valsartan 20, 80, 160, and 320 mg with …

This study was done to assess the antihypertensive efficacy of once-daily valsartan 20 mg,
80 mg, 160 mg, and 320 mg over 24 hours using ambulatory blood pressure monitoring …

Objective To compare the antihypertensive efficacy of a new angiotensin II antagonist,
valsartan, with a reference therapy, amlodipine. Methods One hundred sixty‐eight adult …